APN raises FY 2027 guidance: EBITDA above ZAR 9bn, NHEPS growth over 50%
Aspen Pharmacare (APN) raised FY 2027 guidance, targeting EBITDA over ZAR 9 billion and NHEPS growth above 50%, alongside stronger free cash flow.
Delivered strong EBITDA and NHEPS growth despite flat revenue, driven by operational efficiencies, APAC divestment, and robust commercial pharma and manufacturing performance.
FY 2027 guidance targets over 50% NHEPS growth, ZAR 9 billion EBITDA, and stronger free cash flow.Based on Aspen Pharmacare…